TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma

Inclusion Criteria: * Patients newly diagnosed as HCC according to European Association for Study of the Liver criteria. * BCLC stage A or B * Child-Pugh class A or B (Child-Pugh score 7) * ECOG performance status of 0 * Patients must have at least one tumor lesion that meets both of the following criteria: * The lesion can be accurately measured in at least one dimension according to RECIST criteria * The lesion has not been previously treated with surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation. * Patients who have received previous local therapy treatments (RFA, PEI, cryoablation, surgery, resection) to non-target lesions are eligible * Local therapy must have been completed at least 4 weeks prior to baseline scan. * Haematology:Absolute neutrophil count (ANC) \> 1 x 109/L, Platelet count \> 40 x 109/L, Haemoglobin \> 9 g/dL (may be transfused to maintain or exceed this level) Prothrombin time international normalized ratio \< 1.5 * Biochemistry:Total bilirubin \< 2 mg/dL Serum creatinine \< 1.5 x the upper limit of normal * Ability to understand the protocol and to agree to and sign a written informed consent document Exclusion Criteria: * Tumor factors * Presence of extrahepatic metastasis * Predominantly infiltrative lesion * Diffuse tumor morphology with extensive lesions involving both lobes. * Vascular complications * Hepatic artery thrombosis, or * Partial or complete thrombosis of the main portal vein, or * Tumor invasion of portal branch of contralateral lobe, or * Hepatic vein tumor thrombus, or * Significant arterioportal shunt not amenable to shunt blockage * Liver function * Advanced liver disease: ascites, hepatic encephalopathy * Patients with clinically significant gastrointestinal bleeding within the 30 days prior to study entry. * Others * Renal failure requiring hemo- or peritoneal dialysis * Pregnant or lactating women. * Active sepsis or bleeding. * Hypersensitivity to intravenous contrast agents. * The patient has received prior treatment for HCC target lesion. * History of cardiac disease * Congestive heart failure \> NYHA class 2; active coronary artery disease * Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin. * Hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg despite optimal medical management. * Serious non-healing wounds (including wounds healing by secondary intention), acute or non-healing ulcers, or bone fractures within 3 months. * The patient is, in the opinion of the investigator, unable and / or unwilling to comply with treatment and study instructions. * Substance abuse (current), psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results. * Any active clinically serious infections (\> grade 2 NCI-CTCAE ver 3.0) * HIV infection or AIDS-related illness or serious acute or chronic illness (based on medical history)